Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b vaccine
- Development stage
- Preclinical
- Lead developer
- Rong'an Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b vaccine is a quadrivalent combination vaccine candidate developed by Rong'an Biological, a subsidiary of AIM Vaccine. This vaccine is designed for pediatric use to provide simultaneous protection against four major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and invasive infections caused by Haemophilus influenzae type b (Hib). The formulation typically includes diphtheria and tetanus toxoids, acellular pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin), and the Hib capsular polysaccharide conjugated to a carrier protein. By combining these antigens into a single injection, the vaccine aims to reduce the number of required shots, thereby improving vaccination compliance and simplifying the childhood immunization schedule. It is currently in the preclinical stage of development.
- Other names
- DTaP-Hib combination vaccineQuadruple vaccineDiphtheria-Tetanus-Acellular Pertussis-Haemophilus influenzae type b vaccine
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b vaccine.